Background: Efficient delivery of the poorly water-soluble compound sorafenib still poses a challenge to current formulation strategies. To incorporate the lipophilic molecule into biocompatible and biodegradable theranostic nanoparticles has great potential for improving efficacy and safety of cancer therapy.
Results: In this study, sorafenib nanoencapsulation was optimized using poly(D,L-lactide-co-glycolide) and polyethylene glycol-poly(D,L-lactide-co-glycolide) copolymers comparing three different technologies. The particles ranged in size between 220 and 240 nm with encapsulation efficiencies from 76.1 ± 1.7 % to 69.1 ± 10.1 %. A remarkable maximum drug load of 9.0 % was achieved. Finally, a gadolinium complex was covalently attached to the nanoparticle surface transforming the nanospheres into theranostic devices allowing the localization using magnetic resonance imaging.
Conclusion: The manufacture of sorafenib-loaded nanoparticles and the functionalization of the particle surface with a gadolinium complex resulted in a high drug loading, a strong MRI signal, optimal stability features and a sustained release profile.
Keywords: gadolinium; drug release; polymeric nanocarrier; sorafenib; theranostic nanoparticles
When a peer-reviewed version of this preprint is available in the Beilstein Journals, this information will be updated in the information box above. If no peer-reviewed version is available, please cite this preprint using the following information:
Feczkó, T.; Piiper, A.; Pleli, T.; Schmithals, C.; Denk, D.; Vogl, T. J.; Wacker, M. G. Beilstein Arch. 2019, 20191. doi:10.3762/bxiv.2019.1.v1
|Download RIS (Reference Manager)||Download BIB (BIBTEX)|